{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:05:02Z","timestamp":1785517502086,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Numerous nosocomial infections were observed in hospitals and other healthcare facilities during the COVID-19 pandemic, largely attributed to asymptomatic or pre-symptomatic carriers. SARS-CoV-2 screening data at admission of all hospitalised patients and accompanying persons of a tertiary-care hospital in Germany was included from 1 April 2020 to 31 December 2021. The first oropharyngeal swab of each newly admitted individual was tested for SARS-CoV-2 RNA using reverse transcription polymerase chain reaction (RT-qPCR). The overall testing costs and the costs per positively tested individual were analysed. Out of 111,271 screened individuals, 705 (0.6%) tested positive for SARS-CoV-2 by RT-qPCR. Among these, 236 cases (0.2%) had not been previously diagnosed and were identified through RT-qPCR admission screening. Of the newly detected cases,110 (0.1%) were asymptomatic without any known positive contact history. The specificity of RT-qPCR in screening use was 99.997% (95% CI 99.992\u201399.999%). The mean testing costs of identifying one SARS-CoV-2-positive individual through admission screening was \u20ac8,082.87. Long-term universal RT-qPCR admission screening detected a substantial number of otherwise unidentified SARS-CoV-2-positive individuals, proving its value as a infection control tool with an excellent specificity in screening use during the COVID-19 pandemic. This strategy represents an important lesson learned from the pandemic and may serve as a valuable infection control tool for future pandemics or seasonal pathogen surges.<\/jats:p>","DOI":"10.1186\/s12879-026-14122-8","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:45:13Z","timestamp":1785498313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Universal SARS-CoV-2 RT-qPCR admission screening over 21 months in a German tertiary care hospital: detection of asymptomatic infections"],"prefix":"10.1186","volume":"26","author":[{"given":"Isabella","family":"Eiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Gallasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eisenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Rauschenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"H\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Knies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Prifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Wei\u00dfbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"D\u00f6lken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kampmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Wagenh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1020-6454","authenticated-orcid":false,"given":"Manuel","family":"Krone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"14122_CR1","unstructured":"World Health Organization. Number of COVID-19 deaths reported to WHO (cumulative total) 2024 [cited 2025 07\u201319]. Available from: https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=c"},{"key":"14122_CR2","doi-asserted-by":"crossref","unstructured":"Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538).","DOI":"10.1126\/science.abg3055"},{"issue":"24","key":"14122_CR3","doi-asserted-by":"publisher","first-page":"2100509","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100509","volume":"26","author":"F Campbell","year":"2021","unstructured":"Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance. 2021;26(24):2100509.","journal-title":"Eurosurveillance"},{"key":"14122_CR4","unstructured":"Scientific Pandemic Influenza Group on Modelling Os-gS-M-O. Consensus statement on COVID-19, 3 June 2021: UK Government; 2021 [cited 2024 12\u201331]. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/60c71b97e90e0743acb7a1a4\/S1267_SPI-M-O_Consensus_Statement.pdf"},{"issue":"1","key":"14122_CR5","doi-asserted-by":"publisher","first-page":"14841","DOI":"10.1038\/s41598-023-41841-8","volume":"13","author":"I Nesteruk","year":"2023","unstructured":"Nesteruk I. Endemic characteristics of SARS-CoV-2 infection. Sci Rep. 2023;13(1):14841.","journal-title":"Sci Rep"},{"key":"14122_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.maturitas.2021.05.001","volume":"149","author":"H Cormier","year":"2021","unstructured":"Cormier H, Brangier A, Lefeuvre C, Asfar M, Annweiler C, Legeay C. Lessons learnt from a nosocomial COVID-19 outbreak in a geriatric acute care ward with a high attack rate. Maturitas. 2021;149:34\u20136.","journal-title":"Maturitas"},{"issue":"12","key":"14122_CR7","doi-asserted-by":"publisher","first-page":"e2137257","DOI":"10.1001\/jamanetworkopen.2021.37257","volume":"4","author":"Q Ma","year":"2021","unstructured":"Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(12):e2137257.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"14122_CR8","doi-asserted-by":"publisher","first-page":"e2035057","DOI":"10.1001\/jamanetworkopen.2020.35057","volume":"4","author":"MA Johansson","year":"2021","unstructured":"Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open. 2021;4(1):e2035057.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"14122_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s15010-020-01542-0","volume":"49","author":"L Lanser","year":"2021","unstructured":"Lanser L, Bellmann-Weiler R, \u00d6ttl KW, Huber L, Griesmacher A, Theurl I, et al. Evaluating the clinical utility and sensitivity of SARS-CoV-2 antigen testing in relation to RT-PCR Ct values. Infection. 2021;49(3):555\u20137.","journal-title":"Infection"},{"issue":"5","key":"14122_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ajcp\/aqaa141","volume":"154","author":"ZC Brooks","year":"2020","unstructured":"Brooks ZC, Das S. COVID-19 Testing. Am J Clin Pathol. 2020;154(5):575\u201384.","journal-title":"Am J Clin Pathol"},{"key":"14122_CR11","unstructured":"Bayerisches Landesamt f\u00fcr Gesundheit und Lebensmittelsicherheit (LGL). Coronavirus-Infektionszahlen in Bayern Erlangen2020 [cited 2022 03\u201313]. Available from: https:\/\/www.lgl.bayern.de\/gesundheit\/infektionsschutz\/infektionskrankheiten_a_z\/coronavirus\/karte_coronavirus\/"},{"issue":"5","key":"14122_CR12","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1002\/jmv.26770","volume":"93","author":"S Kr\u00fcger","year":"2021","unstructured":"Kr\u00fcger S, Leskien M, Schuller P, Prifert C, Wei\u00dfbrich B, Vogel U, et al. Performance and feasibility of universal PCR admission screening for SARS-CoV-2 in a German tertiary care hospital. J Med Virol. 2021;93(5):2890\u20138.","journal-title":"J Med Virol"},{"issue":"2","key":"14122_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3201\/eid2702.202318","volume":"27","author":"T Scheier","year":"2021","unstructured":"Scheier T, Schibli A, Eich G, R\u00fcegg C, Kube F, Schmid A, et al. Universal Admission Screening for SARS-CoV-2 Infections among Hospitalized Patients, Switzerland, 2020. Emerg Infect Dis. 2021;27(2):404\u201310.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"14122_CR14","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1038\/s41598-023-33824-6","volume":"13","author":"PW Schreiber","year":"2023","unstructured":"Schreiber PW, Scheier T, Wolfensberger A, Saleschus D, Vazquez M, Kouyos R, et al. Parallel dynamics in the yield of universal SARS-CoV-2 admission screening and population incidence. Sci Rep. 2023;13(1):7296.","journal-title":"Sci Rep"},{"issue":"4","key":"14122_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40273-023-01241-2","volume":"41","author":"T Snowsill","year":"2023","unstructured":"Snowsill T. Modelling the Cost-Effectiveness of Diagnostic Tests. PharmacoEconomics. 2023;41(4):339\u201351.","journal-title":"PharmacoEconomics"},{"key":"14122_CR16","unstructured":"Deutsche Krankenhaus TrustCenter und Informationsverarbeitung GmbH (DKTIG). Universit\u00e4tsklinikum W\u00fcrzburg Leipzig2021 [cited 2024 02\u201314]. Available from: https:\/\/www.deutsches-krankenhaus-verzeichnis.de\/app\/portrait\/3bdd55dbf65b7d59\/start"},{"key":"14122_CR17","unstructured":"Robert Koch Institut. Berichte zu Virusvarianten von SARS-CoV-2 in Deutschland [cited 2023 11\u2009\u2013\u200910]. Available from: https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/DESH\/Berichte-VOC-tab.html"},{"issue":"2","key":"14122_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmi.2022.08.006","volume":"29","author":"I Wagenh\u00e4user","year":"2023","unstructured":"Wagenh\u00e4user I, Knies K, Hofmann D, Rauschenberger V, Eisenmann M, Reusch J, et al. Virus variant-specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022. Clin Microbiol Infect. 2023;29(2):225\u201332.","journal-title":"Clin Microbiol Infect"},{"key":"14122_CR19","unstructured":"Abbott. Predicted Impact of Variants on Abbott\u2019s SARS-CoV-2\/COVID-19 Diagnostic Tests 2022 [cited 2024 09\u2009\u2013\u200903]. Available from: https:\/\/www.molecular.abbott\/content\/dam\/add\/molecular\/products\/infectious-disease\/realtime-sars-cov-2-assay\/sars-cov-2-tech-brief-iterations\/Cross%20Division%20COVID%20Variant%20Tech%20Brief_30%20NOV%202022.pdf"},{"key":"14122_CR20","unstructured":"Centers for Disease Control and Prevention. Symptoms of COVID-19 2022 [cited 2022 10\u201314]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html"},{"key":"14122_CR21","unstructured":"European Medicines Agency. COVID-19 medicines [cited 2024 03\u201308]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines"},{"key":"14122_CR22","unstructured":"Robert Koch Institut. Coronavirus SARS-CoV-2 Berlin [cited 2022 05\u201322]. Available from: https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/nCoV_node"},{"key":"14122_CR23","unstructured":"Kassen\u00e4rztliche Bundesvereinigung Kd\u00f6R. Testungen auf SARS-CoV-2 Berlin [cited 2022 05\u201322]. Available from: https:\/\/www.kbv.de\/html\/themen_49345.php"},{"key":"14122_CR24","unstructured":"Verband der Privaten Krankenversicherung e.V. GKV-Spitzenverband. Deutsche Krankenhausgesellschaft e.V. Vereinbarung nach \u00a7 26 Abs. 2 KHG \u00fcber ein Zusatzentgelt f\u00fcr Testungen auf das Coronavirus SARS-CoV-2 im Krankenhaus 2020 [cited 2025 03\u201312]. Available from: https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/krankenhaeuser\/2020-06-05_Schiedsspruch_KH_Corona-Tests.pdf"},{"key":"14122_CR25","unstructured":"Verband der Privaten Krankenversicherung e.V. GKV-Spitzenverband. Deutsche Krankenhausgesellschaft e.V. Vereinbarung nach \u00a7 26 Abs. 2 KHG \u00fcber ein Zusatzentgelt f\u00fcr Testungen auf das Coronavirus SARS-CoV-2 im Krankenhaus 2021 [cited 2025 03\u201312]. Available from: https:\/\/www.dkgev.de\/fileadmin\/default\/Mediapool\/2_Themen\/2.2_Finanzierung_und_Leistungskataloge\/2.2.6._COVID-19\/2.2.6.11._Vereinbarung_nach____26_Abs._2_KHG\/Vereinbarung_nach____26_Absatz_2_KHG_ueber_ein_Zusatzentgelt_fuer_Testungen_auf_das_Coronavirus_SARS-CoV-2_im_Krankenhaus.pdf"},{"key":"14122_CR26","doi-asserted-by":"crossref","unstructured":"Wagenh\u00e4user I, Knies K, Pscheidl T, Eisenmann M, Flemming S, Petri N et al. SARS-CoV-2 antigen rapid detection tests: test performance during the COVID-19 pandemic and the impact of COVID-19 vaccination. eBioMedicine. 2024;109.","DOI":"10.1016\/j.ebiom.2024.105394"},{"key":"14122_CR27","unstructured":"Bundesministerium f\u00fcr Gesundheit. Verordnung zum Anspruch auf Testung in Bezug auf einen direkten Erregernachweis des Coronavirus SARS-CoV-2 (Coronavirus-Testverordnung \u2013 TestV). 2021."},{"key":"14122_CR28","unstructured":"Bundesministerium f\u00fcr Gesundheit: Verordnung zum Anspruch auf Testung in Bezug auf einen direkten Erregernachweis des Coronavirus SARS-CoV-2 (Coronavirus-Testverordnung \u2013 TestV) vom 8. M\u00e4rz 2021 [Internet]. 2021. Available from: https:\/\/www.bundesanzeiger.de\/pub\/publication\/vY20ZAKpvvOZhomkLfP\/content\/vY20ZAKpvvOZhomkLfP\/BAnz%20AT%2009.03.2021%20V1.pdf?inline (Accessed 1 July 2026)."},{"key":"14122_CR29","unstructured":"Bundesministerium f\u00fcr Gesundheit. Verordnung zum Anspruch auf Testung in Bezug auf einen direkten Erregernachweis des Coronavirus SARS-CoV-2 (Coronavirus-Testverordnung \u2013 TestV) vom 24. Juni 2021. 2021."},{"key":"14122_CR30","unstructured":"Bundesministerium f\u00fcr Gesundheit. Verordnung zur \u00c4nderung der Coronavirus-Impfverordnung und der Coronavirus-Testverordnung vom 16. Dezember 2021. 2021."},{"issue":"1","key":"14122_CR31","doi-asserted-by":"publisher","first-page":"bpad005","DOI":"10.1093\/biomethods\/bpad005","volume":"8","author":"BF Maier","year":"2023","unstructured":"Maier BF, Burdinski A, Wiedermann M, Rose AH, Schlosser F, An der Heiden M, et al. Modeling the impact of the Omicron infection wave in Germany. Biol Methods Protoc. 2023;8(1):bpad005.","journal-title":"Biol Methods Protoc"},{"issue":"3","key":"14122_CR32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/idr13030061","volume":"13","author":"M Zuin","year":"2021","unstructured":"Zuin M, Gentili V, Cervellati C, Rizzo R, Zuliani G. Viral Load Difference between Symptomatic and Asymptomatic COVID-19 Patients: Systematic Review and Meta-Analysis. Infect Dis Rep. 2021;13(3):645\u201353.","journal-title":"Infect Dis Rep"},{"issue":"1","key":"14122_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/thoraxjnl-2020-215042","volume":"76","author":"SH Ra","year":"2021","unstructured":"Ra SH, Lim JS, Kim GU, Kim MJ, Jung J, Kim SH. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. Thorax. 2021;76(1):61\u20133.","journal-title":"Thorax"},{"key":"14122_CR34","unstructured":"Deutsche Gesellschaft f\u00fcr Chirurgie e.V. Gemeinsames Statement von DGCH, DGAI, BDC und BDA zur Wiederaufnahme von elektiven Operationen in deutschen Krankenh\u00e4usern Berlin2020 [cited 2024 09\u2009\u2013\u200903]. Available from: https:\/\/www.dgch.de\/index.php?id=79&L=654&tx_news_pi1%5Bnews%5D=1250&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=66f4769b75acaa89c6ac3fb8147ae9f2"},{"key":"14122_CR35","doi-asserted-by":"publisher","first-page":"105903","DOI":"10.1016\/j.puhe.2025.105903","volume":"247","author":"J Mees","year":"2025","unstructured":"Mees J, Eisenmann M, Pscheidl T, H\u00f6hn A, Ebert S, Roth N, et al. Unveiling hidden cases: Hospital screening as a proxy for SARS-CoV-2 incidence in the general population. Public Health. 2025;247:105903.","journal-title":"Public Health"},{"key":"14122_CR36","unstructured":"\u00c4rzte Zeitung. Was kosten Corona-Intensivpatienten? Neu-Isenburg: Springer Medizin Verlag GmbH. 2021 [cited 2023 05\u201323]. Available from: https:\/\/www.aerztezeitung.de\/Wirtschaft\/Was-kosten-Corona-Intensivpatienten-425104.html"},{"key":"14122_CR37","unstructured":"Olsen JU. Was kosten Corona-Patienten? Leipzig: Mitteldeutscher Rundfunk; [cited 2022 05\u201323]. Available from: https:\/\/www.mdr.de\/nachrichten\/deutschland\/panorama\/corona-behandlung-kosten-100.html"},{"key":"14122_CR38","unstructured":"\u00c4rzte, Zeitung. COVID-19: Kosten f\u00fcr station\u00e4re Behandlung im f\u00fcnfstelligen Bereich Neu-Isenburg: Springer Medizin Verlag GmbH; 2020 [cited 2023 03\u201328]. Available from: https:\/\/www.aerzteblatt.de\/nachrichten\/117521\/COVID-19-Kosten-fuer-stationaere-Behandlung-im-fuenfstelligen-Bereich"},{"issue":"1","key":"14122_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s44158-021-00032-5","volume":"2","author":"S Einav","year":"2022","unstructured":"Einav S, Tankel J. The unseen pandemic: treatment delays and loss to follow-up due to fear of COVID. J Anesth Analg Crit Care. 2022;2(1):5.","journal-title":"J Anesth Analg Crit Care"},{"issue":"1","key":"14122_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jmii.2020.05.001","volume":"54","author":"Z Gao","year":"2021","unstructured":"Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12\u20136.","journal-title":"J Microbiol Immunol Infect"},{"key":"14122_CR41","doi-asserted-by":"publisher","first-page":"102332","DOI":"10.1016\/j.tmaid.2022.102332","volume":"48","author":"S Das","year":"2022","unstructured":"Das S, Samanta S, Banerjee J, Pal A, Giri B, Kar SS, et al. Is Omicron the end of pandemic or start of a new innings? Travel Med Infect Dis. 2022;48:102332.","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"14122_CR42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/infdis\/jiac411","volume":"227","author":"FP Esper","year":"2023","unstructured":"Esper FP, Adhikari TM, Tu ZJ, Cheng YW, El-Haddad K, Farkas DH, et al. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants. J Infect Dis. 2023;227(3):344\u201352.","journal-title":"J Infect Dis"},{"key":"14122_CR43","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants: World Health Organization. 2024 [cited 2024 02\u201302]. Available from: https:\/\/www.who.int\/about\/policies\/terms-of-use"},{"key":"14122_CR44","doi-asserted-by":"crossref","unstructured":"Kang M, Li HP, Tang J, Wang XY, Wang LF, Baele G et al. Changing epidemiological patterns in human avian influenza virus infections. Lancet Microbe. 2024;5(11).","DOI":"10.1016\/S2666-5247(24)00158-7"},{"key":"14122_CR45","unstructured":"Robert Koch Institut. Mpox (fr\u00fcher Affenpocken) 2024 [cited 2024 09\u2009\u2013\u200903]. Available from: https:\/\/www.rki.de\/DE\/Content\/InfAZ\/A\/Affenpocken\/Affenpocken_node.html"},{"key":"14122_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.30538\/psrp-easl2020.0054","volume":"3","author":"TH Rafi","year":"2020","unstructured":"Rafi TH. A holistic comparison between deep learning techniques to determine Covid-19 patients utilizing chest X-Ray images. Eng Appl Sci Lett. 2020;3:85\u201393.","journal-title":"Eng Appl Sci Lett"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14122-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:24:44Z","timestamp":1785515084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-14122-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14122"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14122-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics committee of the University of W\u00fcrzburg reviewed the study protocol and waived the need to formally apply for ethical clearance in accordance with the principles of the Declaration of Helsinki, as the study involved retrospective evaluation of routine data from the clinical information system (file number 20220210 02). Clinical trial number: not applicable. Informed consent to participate was not obtained and was not required because only anonymised retrospective routine data were used. According to Bavarian State law (Art. 27 BayKrG, Bavarian Hospital Act), the use of anonymised data for this purpose does not require explicit informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Manuel Krone receives honoraria and research grants from GSK and Sanofi, as well as non-financial support from Euroimmun unrelated to this work. Isabell Wagenh\u00e4user has received travel support from Swedish Orphan Biovitrum AB outside this work. All other authors declare no financial or non-financial competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1415"}}